Guangdong Jiaying Pharmaceutical Co., Ltd (002198.SZ)
CNY 6.88
(-1.01%)
CNY 6.88
(-1.01%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 40.51 Million CNY | -24.81% |
| 2022 | 53.88 Million CNY | 60.17% |
| 2021 | 33.64 Million CNY | 39.87% |
| 2020 | 24.05 Million CNY | 168.95% |
| 2019 | 8.94 Million CNY | -78.62% |
| 2018 | 41.83 Million CNY | 120.22% |
| 2017 | -206.9 Million CNY | -410.27% |
| 2016 | 66.68 Million CNY | -10.43% |
| 2015 | 74.44 Million CNY | -2.27% |
| 2014 | 76.18 Million CNY | -56.8% |
| 2013 | 176.34 Million CNY | 3398.79% |
| 2012 | 5.04 Million CNY | -74.32% |
| 2011 | 19.62 Million CNY | -13.45% |
| 2010 | 22.67 Million CNY | 61.7% |
| 2009 | 14.02 Million CNY | 10.04% |
| 2008 | 12.74 Million CNY | -46.23% |
| 2007 | 23.7 Million CNY | 2.58% |
| 2006 | 23.1 Million CNY | 49.06% |
| 2005 | 15.5 Million CNY | 445.08% |
| 2004 | 2.84 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -1.75 Million CNY | -1107.7% |
| 2024 Q1 | 6.25 Million CNY | -44.72% |
| 2024 Q2 | 173.81 Thousand CNY | -97.22% |
| 2023 Q4 | 11.31 Million CNY | 46.25% |
| 2023 Q1 | 13.12 Million CNY | -50.1% |
| 2023 FY | 40.51 Million CNY | -24.81% |
| 2023 Q2 | 8.34 Million CNY | -36.4% |
| 2023 Q3 | 7.73 Million CNY | -7.29% |
| 2022 Q1 | 3.88 Million CNY | 224.3% |
| 2022 Q4 | 26.29 Million CNY | 66.86% |
| 2022 Q3 | 15.75 Million CNY | 98.45% |
| 2022 FY | 53.88 Million CNY | 60.17% |
| 2022 Q2 | 7.94 Million CNY | 104.2% |
| 2021 Q1 | 9.57 Million CNY | -52.57% |
| 2021 Q3 | 1.08 Million CNY | 150.51% |
| 2021 Q4 | -3.12 Million CNY | -387.74% |
| 2021 FY | 33.64 Million CNY | 39.87% |
| 2021 Q2 | -2.15 Million CNY | -122.49% |
| 2020 FY | 24.05 Million CNY | 168.95% |
| 2020 Q2 | -4.08 Million CNY | -218.63% |
| 2020 Q1 | 3.44 Million CNY | 102.5% |
| 2020 Q4 | 20.18 Million CNY | 347.09% |
| 2020 Q3 | 4.51 Million CNY | 210.52% |
| 2019 Q3 | 8.67 Million CNY | 40.59% |
| 2019 Q2 | 6.16 Million CNY | -29.31% |
| 2019 Q1 | 8.72 Million CNY | -58.5% |
| 2019 Q4 | -137.71 Million CNY | -1688.09% |
| 2019 FY | 8.94 Million CNY | -78.62% |
| 2018 Q3 | 7.52 Million CNY | 87.11% |
| 2018 Q1 | 9.27 Million CNY | 104.18% |
| 2018 Q2 | 4.02 Million CNY | -56.65% |
| 2018 FY | 41.83 Million CNY | 120.22% |
| 2018 Q4 | 21.02 Million CNY | 179.47% |
| 2017 Q1 | 10.39 Million CNY | -73.06% |
| 2017 FY | -206.9 Million CNY | -410.27% |
| 2017 Q4 | -221.67 Million CNY | -9540.02% |
| 2017 Q3 | 2.34 Million CNY | 16.33% |
| 2017 Q2 | 2.01 Million CNY | -80.58% |
| 2016 FY | 66.68 Million CNY | -10.43% |
| 2016 Q1 | 9.76 Million CNY | -64.36% |
| 2016 Q2 | 9.28 Million CNY | -4.87% |
| 2016 Q4 | 38.58 Million CNY | 326.28% |
| 2016 Q3 | 9.05 Million CNY | -2.52% |
| 2015 FY | 74.44 Million CNY | -2.27% |
| 2015 Q4 | 27.39 Million CNY | 137.32% |
| 2015 Q3 | 11.54 Million CNY | -45.83% |
| 2015 Q2 | 21.3 Million CNY | 49.96% |
| 2015 Q1 | 14.2 Million CNY | -45.31% |
| 2014 Q3 | 11.03 Million CNY | -40.83% |
| 2014 Q4 | 25.97 Million CNY | 135.41% |
| 2014 Q1 | 20.51 Million CNY | -87.02% |
| 2014 FY | 76.18 Million CNY | -56.8% |
| 2014 Q2 | 18.65 Million CNY | -9.08% |
| 2013 Q3 | 10.21 Million CNY | 90.91% |
| 2013 Q4 | 157.99 Million CNY | 1446.14% |
| 2013 FY | 176.34 Million CNY | 3398.79% |
| 2013 Q1 | 2.77 Million CNY | -31.22% |
| 2013 Q2 | 5.35 Million CNY | 93.02% |
| 2012 Q4 | 4.03 Million CNY | 11.32% |
| 2012 Q1 | -2.1 Million CNY | -119.71% |
| 2012 Q3 | 3.62 Million CNY | 812.47% |
| 2012 FY | 5.04 Million CNY | -74.32% |
| 2012 Q2 | -508.34 Thousand CNY | 75.85% |
| 2011 Q2 | -646.41 Thousand CNY | -108.09% |
| 2011 Q4 | 10.67 Million CNY | 565.91% |
| 2011 Q3 | 1.6 Million CNY | 348.09% |
| 2011 Q1 | 7.99 Million CNY | -17.94% |
| 2011 FY | 19.62 Million CNY | -13.45% |
| 2010 Q2 | 3.92 Million CNY | -0.37% |
| 2010 FY | 22.67 Million CNY | 61.7% |
| 2010 Q3 | 5.07 Million CNY | 29.43% |
| 2010 Q1 | 3.93 Million CNY | -22.59% |
| 2010 Q4 | 9.73 Million CNY | 91.76% |
| 2009 Q2 | 1.75 Million CNY | -43.42% |
| 2009 Q3 | 4.07 Million CNY | 131.8% |
| 2009 Q4 | 5.08 Million CNY | 24.89% |
| 2009 FY | 14.02 Million CNY | 10.04% |
| 2009 Q1 | 3.1 Million CNY | 35.42% |
| 2008 Q4 | 2.29 Million CNY | -47.42% |
| 2008 Q2 | 2.04 Million CNY | -49.47% |
| 2008 Q1 | 4.04 Million CNY | -52.45% |
| 2008 FY | 12.74 Million CNY | -46.23% |
| 2008 Q3 | 4.36 Million CNY | 113.46% |
| 2007 FY | 23.7 Million CNY | 2.58% |
| 2007 Q2 | 5.57 Million CNY | 40.37% |
| 2007 Q1 | 3.97 Million CNY | -63.1% |
| 2007 Q3 | 5.64 Million CNY | 1.31% |
| 2007 Q4 | 8.5 Million CNY | 50.58% |
| 2006 Q3 | 5.43 Million CNY | 0.0% |
| 2006 Q4 | 10.76 Million CNY | 97.99% |
| 2006 FY | 23.1 Million CNY | 49.06% |
| 2005 FY | 15.5 Million CNY | 445.08% |
| 2004 FY | 2.84 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Zhejiang Int'l Group Co.,Ltd. | 825.98 Million CNY | 95.095% |
| Zhejiang Zhenyuan Share Co., Ltd. | 113.04 Million CNY | 64.159% |
| Hunan Jingfeng Pharmaceutical Co.,Ltd. | -104.37 Million CNY | 138.816% |
| Hubei Guangji Pharmaceutical Co., Ltd. | -141.05 Million CNY | 128.724% |
| Yifan Pharmaceutical Co., Ltd. | -882.71 Million CNY | 104.59% |
| Sichuan Kelun Pharmaceutical Co., Ltd. | 3.65 Billion CNY | 98.891% |
| Chongqing Lummy Pharmaceutical Co., Ltd. | -56.7 Million CNY | 171.448% |
| Boai NKY Medical Holdings Ltd. | 585.23 Million CNY | 93.077% |
| Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. | 344.97 Million CNY | 88.255% |